Rapid Micro Biosystems (RPID) EBT Margin (2020 - 2026)
Rapid Micro Biosystems (RPID) reported EBT Margin of 178.29% for Q1 2026, down 2207.0% on a YoY basis from 8.46% in Q1 2025, and down 61.14% sequentially from 110.65% in Q4 2025.
Rapid Micro Biosystems (RPID) EBT Margin (2020 - 2026) Analysis & Trends
Rapid Micro Biosystems (RPID) has 7 years of EBT Margin data on file, last reported at 178.29% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin fell 2207.0% year-over-year to 178.29%; the trailing twelve-month figure through Mar 2026 stood at 145.69% (up 545.0% YoY), and the FY2025 full-year result was 140.18%, up 2690.0% from the prior year.
- EBT Margin declined to 178.29% in Q1 2026, from 110.65% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 110.65% in Q4 2025 to a low of 375.86% in Q4 2022.
- A 5-year average of 225.42% and a median of 189.83% in 2024 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin tumbled 16229 bps in 2022 and soared 19969 bps in 2023, its largest moves.
- Tracing RPID's EBT Margin over 5 years: stood at 375.86% in 2022, then soared by 53 bps to 176.17% in 2023, then jumped by 33 bps to 117.73% in 2024, then rose by 6 bps to 110.65% in 2025, then slumped by 61 bps to 178.29% in 2026.
- Business Quant data shows RPID's EBT Margin at 178.29% in Q1 2026, 110.65% in Q4 2025, and 146.68% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.98% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 14.12% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 18.70% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 22.33% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 27.84% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 22.61% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 4.87% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.84% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Rapid Micro Biosystems | 90.41 Mn | 80.98 Mn | 371,000.00 | -178.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -178.29% |
| Dec 31, 2025 | -110.65% |
| Sep 30, 2025 | -146.68% |
| Jun 30, 2025 | -163.14% |
| Mar 31, 2025 | -156.22% |
| Dec 31, 2024 | -117.73% |
| Sep 30, 2024 | -148.74% |
| Jun 30, 2024 | -189.83% |
| Mar 31, 2024 | -237.37% |
| Dec 31, 2023 | -176.17% |
| Sep 30, 2023 | -217.77% |
| Jun 30, 2023 | -280.09% |
| Mar 31, 2023 | -275.67% |
| Dec 31, 2022 | -375.86% |
| Sep 30, 2022 | -344.63% |
| Jun 30, 2022 | -355.00% |
| Mar 31, 2022 | -358.34% |
| Dec 31, 2021 | -279.78% |
| Sep 30, 2021 | -361.89% |
| Jun 30, 2021 | -192.71% |